Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Tofacitinib MR Formulations in Healthy Adults
NCT03112148Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tofacitinib in juvenile idiopathic arthritis (JIA) (6 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Extrapolated Infinite Time at 48 hours, Area Under the Curve From Time Zero to Last Quantifiable Concentration at 48 hours and 2 more. Started Sep 2017; status: completed.
02
Drugs
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT03112148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03112148.